The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Ishares Nasdaq Biotechnology

Nasdaq: IBB
Last

(U.S.) $306.61

Today's change+6.81 +2.27%
Updated December 26 4:00 PM -5GMT. Delayed by at least 15 minutes.
 

Ishares Nasdaq Biotechnology

Nasdaq: IBB
Last

(U.S.) $306.61

Today's change+6.81 +2.27%
Updated December 26 4:00 PM -5GMT. Delayed by at least 15 minutes.

Ishares Nasdaq Biotechnology crosses above 20-day moving average

Ishares Nasdaq Biotechnology closed up sharply Friday, rallying (U.S.)$6.81 or 2.27% to (U.S.)$306.61 and crossing above its 20-day moving average. Shares have lost 3.34% over the last five days, but sit 3.93% below their 52-week high. This security has outperformed the S&P 500 by 22.32% during the last year.

Key company metrics

  • Open(U.S.) $302.23
  • Previous close(U.S.) $299.80
  • High(U.S.) $307.06
  • Low(U.S.) $301.52
  • Bid / Ask-- / --
  • YTD % change+35.03%
  • Volume834,004
  • Average volume (10-day)1,993,701
  • Average volume (1-month)1,537,251
  • Average volume (3-month)1,546,016
  • 52-week range(U.S.) $207.48 to (U.S.) $319.14
  • Beta0.92
  • Trailing P/E4.74×
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend(U.S.) $0.45
  • Dividend yield0.15%
  • Trailing EPS(U.S.) $64.65
Updated December 26 4:00 PM -5GMT. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2014Q2/2014Q4/2013Q2/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201403/31/2014Sep 30, 201309/30/2013Mar 31, 201303/31/2013Sep 30, 201209/30/2012
Revenue98510
Total other revenue--------
Total revenue98510
Gross profit--------
Total cost of revenue--------
Total operating expense11855
Selling / general / administrative11855
Research & development--------
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-20-16
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax446878259291
Income after tax446878259291
Income tax, total0000
Net income446878259291
Total adjustments to net income--------
Net income before extra. items446878259291
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items446878259291
Inc. avail. to common incl. extra. items446878259291
Diluted net income446878259291
Dilution adjustment0------
Diluted weighted average shares23191517
Diluted EPS excluding extraordinary itemsvalue per share19.0345.6216.7617.18
Dividends per sharevalue per share0.000.070.100.53
Diluted normalized EPSvalue per share19.0345.6216.7617.18